Recap: Gilead Sciences Q3 Earnings

Shares of Gilead Sciences GILD rose 1.6% after the company reported Q3 results.

Quarterly Results

Earnings per share rose 20.57% over the past year to $2.11, which beat the estimate of $1.95.

Revenue of $6,577,000,000 higher by 17.36% year over year, which beat the estimate of $6,390,000,000.

Guidance

Gilead Narrows FY20 Adj. EPS Guidance From $6.25-$7.65 To $6.25-$6.60 vs $6.98 Est., Sees Sales $23B-$23.5B vs $24.17B Est.

Conference Call Details

Date: Oct 28, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/kvs5mr23

Recent Stock Performance

52-week high: $85.97

Company's 52-week low was at $59.40

Price action over last quarter: down 15.31%

Company Overview

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.